Effect of 23-gauge Sutureless Vitrectomy & Preoperative Bevacizumab on Results of Diabetic Vitrectomy.
10.3341/jkos.2011.52.3.285
- Author:
Dae Heon HAN
1
;
Hee Jin SOHN
;
Dae Young LEE
;
Dong Heun NAM
Author Information
1. Department of Ophthalmology, Gachon University Gil Hospital, Incheon, Korea. eyedawns@gilhospital.com
- Publication Type:Original Article
- Keywords:
20-gauge vitrectomy;
23-gauge vitrectomy;
Intravitreal bevacizumab injection
- MeSH:
Antibodies, Monoclonal, Humanized;
Diabetic Retinopathy;
Eye;
Humans;
Postoperative Complications;
Retinal Perforations;
Retrospective Studies;
Visual Acuity;
Vitrectomy;
Vitreous Hemorrhage;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2011;52(3):285-292
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate the results of 23-gauge sutureless vitrectomy and preoperative bevacizumab in diabetic retinopathy cases. METHODS: A total of 212 eyes received pars plana vitrectomy by a single surgeon for proliferative diabetic retinopathy and were followed up for at least 6 months. The change of visual acuity and operative complications among the 20-gauge vitrectomy (group I, 86 eyes), 23-gauge vitrectomy (group II, 30 eyes), and 23-gauge vitrectomy with preoperative intravitreal bevacizumab (IVB) injection (group III, 96 eyes) were retrospectively analyzed. RESULTS: One month postoperatively, visual improvement was better in groups II and III than in group I. Three months postoperatively, visual improvement was better in group III than in groups I and II. Six months postoperatively, visual improvement in group III was better than in group I, but there was no significant difference between group II and III. Intraoperative retinal breaks and postoperative vitreous hemorrhage were less common in group III than in groups I and II. CONCLUSIONS: In patients with proliferative diabetic retinopathy, 23-gauge sutureless vitrectomy showed faster visual recovery compared with 20-gauge vitrectomy, and vitrectomy with preoperative bevacizumab had less intraoperative and postoperative complications than vitrectomy without preoperative bevacizumab.
